# Haleon plc (HLN) Stock Analysis: Analysts See a 28.73% Upside for This Healthcare Giant

- Link: https://www.directorstalkinterviews.com/haleon-plc-hln-stock-analysis-analysts-see-a-28-73-upside-for-this-healthcare-giant/4121253137
- Published: 2026-06-08T10:19:27+01:00
- Author: Madison Wilson

Haleon plc (HLN), a United Kingdom-based leader in the healthcare sector, has been
capturing investor attention with its robust portfolio of consumer healthcare products.
With a market capitalization of $40.34 billion, the company is a formidable player
in the Drug Manufacturers – Specialty & Generic industry, offering a wide range 
of oral health, vitamins, supplements, and over-the-counter products across the 
globe.

Currently trading at $9.12, Haleon’s stock presents an intriguing opportunity for
investors, boasting a potential upside of 28.73% based on analyst target prices.
The stock’s 52-week range between $8.70 and $11.27 indicates some volatility, yet
it remains an attractive prospect, particularly given its competitive positioning
and diverse product lineup.

Haleon’s financials, while lacking some traditional valuation metrics like a trailing
P/E ratio or PEG ratio, show a forward P/E of 14.94. This suggests that investors
are anticipating earnings growth, a sentiment bolstered by the company’s modest 
revenue growth of 0.60% and an earnings per share (EPS) of 0.50. Furthermore, Haleon’s
return on equity stands at a healthy 10.27%, demonstrating effective management 
of shareholder investments.

The company also offers investors a dividend yield of 2.12%, with a payout ratio
of 37.08%, suggesting a balanced approach to rewarding shareholders while retaining
earnings for future growth. This combination of income and growth potential makes
Haleon an attractive option for a variety of investment strategies.

Analyst ratings provide additional insight into Haleon’s market standing. With 4
buy ratings and 1 hold rating, there is a consensus leaning towards bullish sentiment.
The average target price of $11.74 underscores the stock’s potential for appreciation,
offering investors a reason to consider adding Haleon to their portfolios.

From a technical perspective, Haleon’s stock is currently trading below both its
50-day ($9.41) and 200-day ($9.75) moving averages, which may signal a buying opportunity
for value-focused investors. However, the relative strength index (RSI) of 23.16
indicates that the stock is in oversold territory, which could mean a price rebound
is imminent.

Haleon’s extensive product offerings, including well-known brands like Sensodyne,
Centrum, and Advil, provide a strong foundation for growth across multiple regions,
including North America, Europe, and Asia Pacific. The company’s historical roots
dating back to 1715 and its recent transformation from DRVW 2022 plc to Haleon plc
in 2022 reflect its adaptive nature and long-standing presence in the healthcare
industry.

For investors seeking exposure to the healthcare sector with a focus on consumer
products, Haleon presents a compelling case. The potential upside, combined with
a steady dividend and positive analyst outlook, positions the company as a strong
contender for both growth and income-focused portfolios.

Share on: